Title :

HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment

Author(s) :

Ghosn, Jade [Auteur]
Bachelet, Delphine [Auteur]
Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique [CIC 1425]
Département d'épidémiologie, biostatistique et recherche clinique
Livrozet, Marine [Auteur]
CIC - HEGP [CIC 1418]
CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris] [DMU CARTE]
Cervantes-Gonzalez, Minerva [Auteur]
Rétrovirologie Moléculaire
Poissy, Julien [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Goehringer, François [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Gandonniere, Charlotte Salmon [Auteur]
Centre d’Investigation Clinique [Tours] CIC 1415 [CIC]
Maillet, Mylène [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Bani-Sadr, Firouzé [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Martin-Blondel, Guillaume [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Centre de Physiopathologie Toulouse Purpan [CPTP]
Tattevin, Pierre [Auteur]
Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes]
Launay, Odile [Auteur]
CIC Cochin Pasteur [CIC 1417]
AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
Université Paris Descartes - Paris 5 [UPD5]
Université Sorbonne Paris Cité [USPC]
Surgers, Laure [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Centre d'Immunologie et des Maladies Infectieuses [CIMI]
Dudoignon, Emmanuel [Auteur]
Marqueurs cardiovasculaires en situation de stress [MASCOT (UMR_S_942 / U942)]
Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
Liegeon, Geoffroy [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Zucman, David [Auteur]
Hôpital Foch [Suresnes]
Joseph, Cédric [Auteur]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 [AGIR ]
CHU Amiens-Picardie
Senneville, Eric [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Yelnik, Cécile [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Roger, Pierre-Marie [Auteur]
Régulations des réactions immunitaires et inflammatoires
Hôpital l'Archet
Centre Hospitalier Universitaire de Nice [CHU Nice]
CHU Pointe-à-Pitre / Abymes [Guadeloupe]
Faure, Karine [Auteur]
Gousseff, Marie [Auteur]
Cabié, André [Auteur]
Duval, Xavier [Auteur]
Chirouze, Catherine [Auteur]
Laouénan, Cédric [Auteur]

Journal title :

Journal of Antimicrobial Chemotherapy

Pages :

346-353

Publisher :

Oxford University Press (OUP)

Publication date :

2023-02-01

ISSN :

0305-7453

English keyword(s) :

Cohort
Emerging infectious diseases
Moderate to severe COVID-19
Post-acute COVID-19 symptoms
SARS-CoV-2

HAL domain(s) :

Sciences du Vivant [q-bio]/Immunologie

English abstract : [en]

Objectives : To evaluate the routine use of the Sentosa ultra-deep sequencing (UDS) system for HIV-1 polymerase resistance genotyping in treatment-naïve individuals and to analyse the virological response (VR) to first-line ...
Show more >Objectives : To evaluate the routine use of the Sentosa ultra-deep sequencing (UDS) system for HIV-1 polymerase resistance genotyping in treatment-naïve individuals and to analyse the virological response (VR) to first-line antiretroviral treatment. Methods : HIV drug resistance was determined on 237 consecutive samples from treatment-naïve individuals using the Sentosa UDS platform with two mutation detection thresholds (3% and 20%). VR was defined as a plasma HIV-1 virus load <50 copies/mL after 6 months of treatment. Results : Resistance to at least one antiretroviral drug with a mutation threshold of 3% was identified in 29% and 16% of samples according to ANRS and Stanford algorithms, respectively. The ANRS algorithm also revealed reduced susceptibility to at least one protease inhibitor (PI) in 14.3% of samples, to one reverse transcriptase inhibitor in 12.7%, and to one integrase inhibitor (INSTI) in 5.1%. For a mutation threshold of 20%, resistance was identified in 24% and 13% of samples according to ANRS and Stanford algorithms, respectively. The 6 months VR was 87% and was similar in the 58% of patients given INSTI-based treatment, in the 16% given PI-based treatment and in the 9% given NNRTI-based treatment. Multivariate analysis indicated that the VR was correlated with the baseline HIV virus load and resistance to at least one PI at both 3% and 20% mutation detection thresholds (ANRS algorithm). Conclusions : The Vela UDS platform is appropriate for determining antiretroviral resistance in patients on a first-line antiretroviral treatment. Further studies are needed on the use of UDS for therapeutic management.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167

Source :

Harvested from HAL